TY  - JOUR
A1  - Adelfinger, Marion
A1  - Gentschev, Ivaylo
A1  - de Guibert, Julio Grimm
A1  - Weibel, Stephanie
A1  - Langbein-Laugwitz, Johanna
A1  - Härtl, Barbara
A1  - Escobar, Hugo Murua
A1  - Nolte, Ingo
A1  - Chen, Nanhai G.
A1  - Aguilar, Richard J.
A1  - Yu, Yong A.
A1  - Zhang, Qian
A1  - Frentzen, Alexa
A1  - Szalay, Aladar A.
T1  - Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
JF  - PLoS ONE
N2  - Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis.
In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model.
KW  - antibodies
KW  - cancer treatment
KW  - carcinomas
KW  - vaccinia virus
KW  - oncolytic viruses
KW  - viral replication
KW  - cell cultures
KW  - enzyme-linked immunoassays
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119387
VL  - 9
IS  - 8
ER  - 
TY  - JOUR
A1  - Donat, Ulrike
A1  - Rother, Juliane
A1  - Schäfer, Simon
A1  - Hess, Michael
A1  - Härtl, Barbara
A1  - Kober, Christina
A1  - Langbein-Laugwitz, Johanna
A1  - Stritzker, Jochen
A1  - Chen, Nanhai G.
A1  - Aguilar, Richard J.
A1  - Weibel, Stephanie
A1  - Szalay, Alandar A.
T1  - Characterization of Metastasis Formation and Virotherapy in the Human C33A Cervical Cancer Model
JF  - PLoS ONE
N2  - More than 90% of cancer mortalities are due to cancer that has metastasized. Therefore, it is crucial to intensify research on metastasis formation and therapy. Here, we describe for the first time the metastasizing ability of the human cervical cancer cell line C33A in athymic nude mice after subcutaneous implantation of tumor cells. In this model, we demonstrated a steady progression of lumbar and renal lymph node metastases during tumor development. Besides predominantly occurring lymphatic metastases, we visualized the formation of hematogenous metastases utilizing red fluorescent protein (RFP) expressing C33A-RFP cells. RFP positive cancer cells were found migrating in blood vessels and forming micrometastases in lungs of tumor-bearing mice. Next, we set out to analyze the influence of oncolytic virotherapy in the C33A-RFP model and demonstrated an efficient virus-mediated reduction of tumor size and metastatic burden. These results suggest the C33A-RFP cervical cancer model as a new platform to analyze cancer metastases as well as to test novel treatment options to combat metastases.
KW  - metastasis
KW  - renal cancer
KW  - oncolytic viruses
KW  - lymph nodes
KW  - kidneys
KW  - lung and intrathoracic tumors
KW  - secondary lung tumors
KW  - cancer treatment
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119674
SN  - 1932-6203
VL  - 9
IS  - 6
ER  -